Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers by L. Breda et al.
Brief Report
RED CELLS, IRON, AND ERYTHROPOIESIS
Forced chromatin looping raises fetal hemoglobin in adult sickle cells to
higher levels than pharmacologic inducers
Laura Breda,1,2 Irene Motta,1,3 Silvia Lourenco,1,2 Chiara Gemmo,1 Wulan Deng,4 Jeremy W. Rupon,2
Osheiza Y. Abdulmalik,2 Deepa Manwani,5 Gerd A. Blobel,2,* and Stefano Rivella1,2,*
1Department of Pediatrics, Division of Hematology-Oncology, Children’s Blood and Cancer Foundation Laboratories, Weill Cornell Medical College,
New York, NY; 2Department of Pediatrics, Division of Hematology, Children’s Hospital of Philadelphia, Philadelphia, PA; 3Department of Clinical Science
and Community Health, University of Milan, Milan, Italy; 4Transcription Imaging Consortium, Janelia Research Campus, Howard Hughes Medical Institute,
Ashburn, VA; and 5Department of Pediatrics, Albert Einstein College of Medicine, Children’s Hospital at Montefiore, Bronx, NY
Key Points
• Ldb1 transcription factor self-
association domain fused to
g-globin promoter-specific
ZF protein increases HbF,
reduces HbS in hSCD cells.
• In vitro reactivation of HbF
mediated by ZF-Ldb1
exceeds pharmacologic
treatment in adult hSCD cells.
Overcoming the silencing of the fetal g-globin gene has been a long-standing goal in the
treatment of sickle cell disease (SCD). Themajor transcriptional enhancer of the b-globin
locus,called the locuscontrol region (LCR),dynamically interactswith thedevelopmental
stage-appropriate b-type globin genes via chromatin looping, a process requiring the
protein Ldb1. In adult erythroid cells, the LCR can be redirected from the adult b- to the
fetal g-globin promoter by tethering Ldb1 to the human g-globin promoter with custom-
designed zinc finger (ZF) proteins (ZF-Ldb1), leading to reactivation of g-globin gene
expression. To compare this approach to pharmacologic reactivation of fetal hemoglobin
(HbF), hematopoietic cells frompatientswithSCDwere treatedwith a lentivirus expressing
the ZF-Ldb1 orwith chemical HbF inducers. The HbF increase in cells treatedwith ZF-Ldb1
wasmore than double that observedwith decitabine and pomalidomide; butyrate had an
intermediate effectwhereas tranylcypromine andhydroxyurea showed relatively lowHbF
reactivation. ZF-Ldb1 showed comparatively little toxicity, and reduced sickle hemoglo-
bin (HbS) synthesis aswell as sickling of SCDerythroid cells under hypoxic conditions. The efficacy and lowcytotoxicity of lentiviral-
mediated ZF-Ldb1 gene transfer compared with the drug regimens support its therapeutic potential for the treatment of SCD. (Blood.
2016;128(8):1139-1143)
Introduction
Sickle cell disease (SCD) represents a major challenge and a growing
health problem inWestern countries,with;300 000births everyyear.1
Altered deformability of sickle cells is caused by the polymerization
of deoxygenated sickle hemoglobin (HbS), whose rate and extent
are proportional to the extent and duration of hemoglobin (Hb)
deoxygenation and the levels of fetal hemoglobin (HbF) in the
erythrocyte.2 As a consequence, patients experience vaso-occlusive
crises and red cell destruction in the peripheral circulation.3 Since the
discovery that patients with hereditary persistence of HbF have a more
benign clinical course,4 considerable research has been devoted to-
ward approaches to augment HbF levels in adult red blood cells.
Hydroxyurea (HU) is theonlyapproveddrug to induceHbF.5Although
its use is associated with marked clinical improvement, patients’
compliance and concerns about long-term effects hinder widespread
utilization.6
Despite the improvement in the management of SCD, allogeneic
hematopoietic stem cell transplantation remains the only curative
option.7 New approaches from alternative donors showed promising
results, however, they are limited to experimental protocols.8
Gene transfer using autologous bone marrow is a suitable option to
cure SCD, and could resolve the issue of amatched donor and eliminate
the risks of graft-versus-host disease.9 In recent clinical trials, the
successful use of lentiviral vectors carrying theb- org-globin genes9,10
has opened the doors to other approaches, based on knockdown of
g-globin repressors and genome editing.11-13
Study design
We have developed another approach in which long-range enhancer-promoter
contacts canbe establishedby zincﬁnger (ZF)-mediated tetheringof the “looping
factor” Ldb1, leading to transcriptional activation.14 In murine and human
adult erythroid cells from healthy individuals, this approach was successful in
activating embryonic and fetal globin genes, respectively, thus partially reversing
the developmental gene switch.15
The aim of this study was to compare the forced chromatin-looping strategy
to known pharmacologic HbF inducers in adult erythroid cells from patients
with SCD.
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Figure 1. Increased HbF and reduced HbS synthesis after treatment with pCL-ZF-Ldb1. (A) Lentiviral construct carrying ZF-Ldb1 and the GFP genes expressed under the
ankyrin promoter (Pr) via an internal ribosomal entry site (IRES). (B) Percentage of HbF, HbS, and HbA2 measured by high-performance liquid chromatography (HPLC) in representative
erythroid cells untreated (top) or treated with ZF-Ldb1 (bottom). The transduced cells have, on average, 0.7 copies of viral molecules integrated per genome. (C) Changes in percentage
of cells expressing HbF (left panels) and GFP (right panels), measured by flow cytometry. (D) Overall percentages of HbF, HbS, and HbA2 changes in SCD samples treated with pCL-
ZF-Ldb1 (n 5 10, 5 samples were duplicated; average VCN5 1.2). (E) Hb (F 1 S 1 A2) content in erythroid cells with or without pCL-ZF-Ldb1. (F) Ratio of b- or g-globin chains over
a-globin chains. The quantity of the globin chains (in mg) is measured via liquid chromatography under denaturing conditions (**P, .05). (G) Ratio of g/b-like chains measured in
250 000 erythroid sickle cells untreated or treated with pCL-ZF-Ldb1 (n5 5, VCN5 1.6; ***P, .005 and **P, .05). FSC-H, forward scatter height; LTR, long terminal repeat; pA,
polyadenylation signal; pCL, vector backbone; VCN, vector copy number; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element.
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Figure 2. Variation of HbF and HbS levels in CD341-derived SCD erythroid cells treated with pCL-ZF-Ldb1 LV or HbF inducers in vitro. (A) Schematic representation
of the experimental protocol of human SCDCD341 cells treated with the inducer drugs or pCL-ZF-Ldb1. (B) Erythroid cell number (by benzidine staining; N5 2) using the indicated
doses of drugs and compared with pCL-ZF-Ldb1 (with VCN ;1 copy per cell). Black arrows indicate the dose of each drug chosen for the subsequent experiments. (C) Net
increase of HbF percentage and (D) net decrease of HbS percentage in SCD erythroblasts (N 5 7, 2 of which were replicated once or twice, respectively) treated with the HbF
inducers or pCL-ZF-Ldb1 (***P , .005). (E) Erythroid cell count for each treatment normalized to count of untreated samples (*P 5 .05, **P , .05). (F) Morphological assessment
of untreated (ctrl, left) vs pCL-ZF-Ldb1–treated cells (right) in hypoxic conditions. (G) Proportion of sickled cells/total cell count and (H) relative means and SD, measured on
3 replicas on 3 sets of samples treated with the various inducers or pCL-ZF-Ldb1 (**P, .05, ***P, .005) and exposed to hypoxic conditions. P values under and above bars refer
to differences between treated and untreated samples and between treated samples, respectively. 5-AZA, 5-aza-29-deoxy-cytidine; But, butyrate; ND, not determined; PBMC,
peripheral blood mononuclear cell; Pom/Pomalid., pomalidomide; SD, standard deviation; TCP, tranyl-cypromine.
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Results and discussion
We aimed to improve HbF synthesis and the quality of erythroid
cells derived from patients with SCD, using the lentiviral vector
(pCL20cAnkyrinGG1DDiGFP), henceforth called pCL-ZF-
Ldb1 (Figure 1A), which enabled Hb switch in healthy erythroblasts.15
As expected, sickle CD341 cells produced predominantly HbS (a2b
s
2)
once differentiated into erythroblasts in vitro (Figure 1B top). Other Hb,
such as HbF (a2g2) and HbA2 (a2d2), were produced to a lower degree
(Figure1B top).Following infectionwithpCL-ZF-Ldb1vector, the same
SCD-derived erythroid cells increased the proportion of HbF and green
ﬂuorescent protein (GFP)-expressing erythroblasts (Figure 1C; supple-
mental Figure 1, available on the BloodWeb site) and HbF from 10.3%
(Figure 1B top) to 54.6% (Figure 1B bottom).
We analyzed the messenger RNA and Hb protein content of eryth-
roblasts, untreated or after transduction with pCL-ZF-Ldb1, derived
from 10 SCD subjects. On average, cells treated with pCL-ZF-Ldb1
produced nearly 40% more HbF compared with untreated cells (from
27.26% to 65.52%) and lowered production of HbS (231.14%; from
62.83% to 31.69%) and HbA2 (24.5%; from 9.5% to 5%) (Figure 1D).
Messenger RNA content of g-, b-, d-globins and transgenic Ldb1
changed accordingly (supplemental Figure 2).
To assess the effect of ZF-Ldb1 treatment on the total amount of
cellular Hb, we measured absolute Hb content in differentiated cells.
TotalHb synthesis (HbF1HbS1HbA2) remained essentially unaltered
(Figure 1E), regardless of signiﬁcant shifts in the ratio of fetal to adult
globin. Reversed-phase liquid chromatography, which allows for the
quantiﬁcation of single globin chains rather than tetrameric hemoglo-
bin molecules, revealed that bS chains were diminished whereas both
gA 1 gG chains were increased in specimens treated with ZF-Ldb1
(Figure 1F-G; supplemental Figure 3).
The experimental outline to compare pCL-ZF-Ldb1 to pharmaco-
logic inducers of HbF is illustrated in Figure 2A. Brieﬂy, SCD ery-
throid progenitor cells were infected with pCL-ZF-Ldb1 or treated
with 5-aza-29-deoxy-cytidine (0.5 mM), tranylcypromine (1.5 mM),
HU (150 mM), pomalidomide (30mM), or butyrate (100 mM).
Concentrations of inducers were determined through evaluation of
efﬁcacy (net increase ofHbF) vs toxicity (cell death); the original scaling
dosage (Figure 2B)was extrapolated from themost recent literature.16-18
Studies were performed at the end of phase 3 (day 18 from initial cell
isolation), at the orthochromatophilic stage when Hb levels peaked.
PCL-ZF-Ldb1–treated cells showed the most robust increase of HbF
(Figure 2C) and decrease in HbS (Figure 2D). On average, the HbF in
control (ctrl) SCD erythroblasts was 10.36% vs 21.05%, 14.16%,
15.98%, 18.91%, 17.34%, and 45.12% after treatment, respectively,
with 5-aza-29-deoxy-cytidine, tranylcypromine, HU, pomalidomide,
butyrate, andZF-Ldb1. In the same samples, on average,HbSdecreased
from 85.6%, in untreated SCD erythroblasts, to 74.8%, 81.7%, 79.1%,
76.9%, 78.1%, and 50.3% after treatments. ZF-Ldb1–expressing cells
presented signiﬁcantly higher variation in HbF and HbS than untreated
and all other treated cells. Along with greater improvement of HbF
levels, cells expressing ZF-Ldb1 did not show signiﬁcant changes in
viability compared with untreated samples, whereas cells treated with
pomalidomide, butyrate, andHU showed reduced viability (Figure 2E).
Moreover, the number of sickled cells in 3 independent samples treated
with pCL-ZF-Ldb1andexposed tohypoxic conditionswas signiﬁcantly
reduced, also showing the least variability, when compared with con-
trols or pharmacologically treated cells (Figure 2F-G). Taken together,
pCL-ZF-Ldb1was superior to all tested compounds in augmentingHbF
and F-cell levels and importantly was associated with minimal toxicity.
Clinical observations indicate that the increase of HbF can ame-
liorate the severity of SCD.Although administration ofHU in patients is
associated with increased HbF levels, its therapeutic effects in children
and adults are extremely variable,with increase ofHbF ranging between
10% and 30%.6,19
Here, we investigated to which extent manipulation of the chroma-
tin organization of the b-globin gene locus, via targeted tethering of
the Ldb1 self-association domain to the b-like gG- and gA-globin pro-
moters, can reverse the developmental gene switch in erythroblasts
derived from SCD patients. We found that sickle erythroblasts treated
with pCL-ZF-Ldb1 can yield up to a 40% increase of HbF synthesis
and concurrently reduce HbS synthesis. Expression of ZF-Ldb1 in
SCD led to 2 major beneﬁcial outcomes, that is, increased HbF and
reduced HbS content. Although the HbF content was 2.3-fold higher in
treated erythroblasts, the overall Hb concentration, comprising HbF,
HbS, and HbA2, remained unchanged, consistent with unimpeded ery-
throid maturation.
ZF-Ldb1 is a relatively small gene construct driven by a short
promoter, which requires relatively low expression levels to activate
the g-globin genes. As small vectors signiﬁcantly simplify pro-
duction of lentiviral particles, this may also represent a considerable
advantage over lentiviral vectors based on a classic additive gene-
therapy approach, like those carrying curative b/g-globin genes,
which require additional large genomic elements to achieve
therapeutic expression levels.20-23 Compared with gene editing and
gene disruption, gene transfer for the cure of b-globinopathies has
been shown to be safe in at least 10 patients.24,25 The therapeutic
implication of our strategy for SCD patients has potential clinical
application, as it not only sustains high levelsof endogenous functional
hemoglobin, but also reduces the quantity of sickled cells in hypoxic
conditions.
In conclusion, a lentiviral vector carrying the self-association Ldb1
domain linked to a ZF protein, which selectively binds the g-globin
promoters, signiﬁcantly increased HbF synthesis and exceeded the
effects of previously described pharmacologic inducers in human
cultured cells. Further lines of investigation will provide additional
insight on the impact of this approach in vivo and on its safety and
applicability for clinical purposes.
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